

# CAN HVTN505 VACCINE PREVENT HIV INFECTION?


---

Hana El Sahly, MD  
Baylor College of Medicine

From Research to the Real World: Sharing Science Symposium  
April 22, 2014

# Why We Did this Study

We came a long way



But not far enough

**Diagnoses of HIV Infection among Adults and Adolescents, by Population of Area of Residence and Region, 2011—United States**

Region of residence	MSA of $\geq 500,000$		MSA of 50,000-499,999		Non-metropolitan	
	No.	Rate	No.	Rate	No.	Rate
<b>Northeast</b> N = 9,883	9,171	24.4	486	10.1	227	4.9
<b>Midwest</b> N = 6,169	4,979	16.2	765	6.3	425	3.3
<b>South</b> N = 24,011	18,041	31.7	3,579	17.8	2,390	12.7
<b>West</b> N = 8,649	7,741	17.6	692	7.0	216	3.6

Note: Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been statistically adjusted to account for reporting delays, but not for incomplete reporting. Rates are per 100,000 population. Data exclude persons whose county of residence is unknown.

# What We Did

		Injection schedule in months (days)			
		Prime			Boost
Group	N*	0 (0)	1 (28)	2 (56)	6 (168)
1	1100	4 mg DNA	4 mg DNA	4 mg DNA	10 <sup>10</sup> PU rAd5
2	1100	PBS	PBS	PBS	FFB

Procedure	Screening visit(s)	Time after first injection visit (in months)											
		First injection visit	1	2	2½	6	7	9	12	15	18	21	24
Informed consent	√												
Medical history	√												
Complete physical	√												√
Brief physical exam		√	√	√	√	√	√	√	√	√	√	√	√
Blood drawn	√	√			√	√	√	√	√	√	√	√	√
HIV testing/counseling	√	√			√	√	√	√	√	√	√	√	√
Questions/questionnaire	√	√	√	√	√	√	√	√	√	√	√	√	√
Outside testing counseling	√	√	√	√	√	√	√	√	√	√	√	√	√
Risk reduction counseling	√	√	√	√	√	√	√	√	√	√	√	√	√
Injection		√	√	√		√							





## HIV Vaccine Trials Network (HVTN) 505 Baylor College of Medicine

- Multisite Phase II study
- Enrolled 2504 gay/bisexual men and transwomen
- BCM/Houston enrolled 60 volunteers
- Age 18-50
- HIV negative
- Circumcised
- Adenovirus 5 negative



# What We Found



# What Our Results Mean and Why this Matters

- The HVTN505 vaccine:
  1. was safe
  2. did not prevent HIV
  3. did not help the level of HIV counts in the blood for those who got infected with HIV
- The search/research for a good HIV vaccine goes on:
  1. Thorough analysis of this clinical trial is still ongoing
  2. Other vaccine constructs will be coming through pipeline

**a cure for  
aids is  
impossible.  
without research.**

[amfAR.org/findthecure](http://amfAR.org/findthecure)

# Acknowledgments

- Our Volunteers
- The research team at the Vaccine Research Center/BCM
- Houston HIV Research Community Advisory Board
- National Institutes of Health-Fred Hutchinson Cancer Research Center
- Baylor-UTHouston Center for AIDS Research